S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
CVE:ERG

16611 (ERG.V) Stock Forecast, Price & News

C$0.30
0.00 (0.00 %)
(As of 02/27/2018)
Add
Compare
Today's Range
C$0.30
C$0.30
50-Day Range
C$0.30
C$0.30
52-Week Range
C$0.22
C$0.30
Volume2,000 shs
Average Volume83,684 shs
Market CapitalizationC$21.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ERG News and Ratings via Email

Sign-up to receive the latest news and ratings for 16611 (ERG.V) and its competitors with MarketBeat's FREE daily newsletter.


About 16611 (ERG.V)

Ergoresearch Ltd. operates in the healthcare sector. The Company manufactures and sells custom foot orthotics and general orthotics, and develops durable medical equipment for the orthopedic market. The Company is engaged in development of orthopedic solutions and products impacting pain management. The Company's products are non-invasive and non-toxic biomechanical devices, which feature patient benefits that are supported by clinical proof and scientific data. The Company designed and commercialized WebFit, a custom-fit orthotics manufacturing software program, and OdrA, an orthotic device. Its range of foot orthotics includes WebFit-Diabetes, WebFit-Gonosteoarthritis and WebFit. Its products also include podo-barometric sensor pads and scanners, and three dimensional (3d) scanner. The Company uses numerical control machine tools to manufacture its foot orthotics. It has approximately 10 laboratories.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry
Electronic Computer Manufacturing
Sub-Industry
N/A
CIK
N/A
Employees
147,000
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
C$21.39 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












16611 (ERG.V) (CVE:ERG) Frequently Asked Questions

What stocks does MarketBeat like better than 16611 (ERG.V)?

Wall Street analysts have given 16611 (ERG.V) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 16611 (ERG.V) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are 16611 (ERG.V)'s key executives?

16611 (ERG.V)'s management team includes the following people:
  • Sylvain Boucher, President, Chief Executive Officer, Director
  • Dominique Boudreau, Vice President - Finance
  • Frederic Petit, Vice President - Operations
  • Danielle Boucher, Vice- President of Clinique du Pied Equilibre, Director
  • Gilles Laporte, Director
  • Catherine Chamouton, Independent Director
  • Michel Pierron, Independent Director
  • Francois Tellier, Independent Director

What is 16611 (ERG.V)'s stock symbol?

16611 (ERG.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ERG."

How do I buy shares of 16611 (ERG.V)?

Shares of ERG and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is 16611 (ERG.V)'s stock price today?

One share of ERG stock can currently be purchased for approximately C$0.30.

How much money does 16611 (ERG.V) make?

16611 (ERG.V) has a market capitalization of C$21.39 million.

How many employees does 16611 (ERG.V) have?

16611 (ERG.V) employs 147,000 workers across the globe.

What is 16611 (ERG.V)'s official website?

The official website for 16611 (ERG.V) is www.ergoresearch.com.

Where are 16611 (ERG.V)'s headquarters?

How can I contact 16611 (ERG.V)?

16611 (ERG.V)'s mailing address is 2101 Le Carrefour Blvd Suite 200, LAVAL, QC H7S 2J7, Canada. The company can be reached via phone at +1-514-9313355.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.